Latest news and press releases about Inovio Pharmaceuticals, Inc. (INO): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases. The company's advanced DNA medicine platform utilizes meticulously engineered SynCon sequences to precisely identify and optimize the genetic blueprint of a target antigen.
Price
| Price | $1.15 |
| Market Cap | $79M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.72 |
| EV / EBITDA | -0.57 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -352.53% |
| Return on Invested Capital | -259.45% |
| Return on Assets | -114.31% |
| Gross Margin | 100.00% |
| Operating Margin | -132871.32% |
| Net Margin | -130000.00% |
Related companies: ABOS · ACTU · AGEN · ALEC · FATE · IRD · MCRB
Explore sector: Healthcare · Biotechnology
More sections of INO: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks